![ImmunityBio, Inc. logo](/logos/IBRX.webp)
ImmunityBio, Inc.
NASDAQ:IBRX
Overview | Financials
Company Name | ImmunityBio, Inc. |
Symbol | IBRX |
Currency | USD |
Price | 3.38 |
Market Cap | 2,354,281,540 |
Dividend Yield | 0% |
52-week-range | 1.25 - 10.53 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Richard Gerald Adcock |
Website | https://immunitybio.com |
An error occurred while fetching data.
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD